The US-FDA has endowed chloroquine and hydroxychloroquine — the pair of malaria drugs as its first emergency use authorization for a Covid-19 treatment, paving the way for hospitals to prescribe a million doses of the medicines that have been donated to the national stockpile.

The FDA noted that this authorization is intended to benefit adult and teen patients who are hospitalized and can’t participate in the handful of clinical trials underway in the US.

“The chloroquine phosphate must be administered by a healthcare provider pursuant to a

valid prescription of a licensed practitioner”

Based on the totality of scientific evidence available to FDA,  the known and potential benefits of chloroquine phosphate and hydroxychloroquinesulfate when used to treat COVID-19 outweigh the known and potential risks of such products.

The suggested dose for:

-chloroquine phosphate is:

1 gram on day 1 followed by 500 mg for 4 to 7 days. 

-As for hydroxychloroquine sulfate, the suggested dose is 800 mg to start and then 400 mg on subsequent days.

Read more: https://www.fda.gov/media/136534/download